| Title | Ranolazine attenuates behavioral signs of neuropathic pain. | | Author(s) | Gould HJ, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK | | Institution | Departments of aNeurology bPharmacology cAnesthesiology dPain Mastery Center of Louisiana, Louisiana State University Health Sciences Center, New Orleans, Louisiana eDepartment of Pharmacology, Tulane University Health Sciences Center fGilead Sciences, Palo Alto, California gDepartment of Physiology, University of Kentucky Medical Center, Lexington, Kentucky, USA. | | Source | Behav Pharmacol 2009 Sep 21. | | Abstract | Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19773645 |
|
